Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Kwapiszewska, G; Hoffmann, J; Kovacs, G; Stacher, E; Olschewski, A; Olschewski, H.
[Pulmonary (Arterial) Hypertension].
Pneumologie. 2016; 70(10):630-637
Web of Science PubMed FullText FullText_MUG

 

Authors Med Uni Graz:
Kovacs Gabor
Kwapiszewska-Marsh Grazyna
Olschewski Andrea
Olschewski Horst
Stacher-Priehse Elvira
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Pulmonary arterial hypertension (PAH) is a rare disease characterised by vascular remodelling of the small lung arteries leading to a decrease of the vessel lumen and eventually to occlusion. According to the current guidelines, PAH is defined by a pulmonary arterial pressure ≥ 25 mmHg, an arterial wedge pressure ≤ 15 mmHg, and an elevated pulmonary vascular resistance (PVR > 3 WU). The current pathophysiological concepts include disturbances in the production, deposition and composition of the extracellular matrix, inflammatory processes, mutations in the BMPR2 gene as well as mutations in the KCNK3 gene. During the last few years, epigenetic and genetic investigations resulted in new findings which are highly relevant for the diagnosis, prognosis and therapy of PAH. These findings could lead to the development of new, individualised therapy strategies. Currently, several phase I and phase II studies are in progress, in which promising new substances are examined. © Georg Thieme Verlag KG Stuttgart · New York.
Find related publications in this database (using NLM MeSH Indexing)
Evidence-Based Medicine -
Genetic Predisposition to Disease - genetics
Genetic Therapy - methods
Humans -
Hypertension, Pulmonary - diagnosis
Hypertension, Pulmonary - genetics
Hypertension, Pulmonary - therapy
Molecular Targeted Therapy - methods
Precision Medicine - methods
Treatment Outcome -

© Med Uni GrazImprint